Activation of inflammatory responses regulates the transmission of pain pathways through an integrated network in the peripheral and central nervous systems.The immunopotentiator thymosin alpha-1(Tal)has recently been...Activation of inflammatory responses regulates the transmission of pain pathways through an integrated network in the peripheral and central nervous systems.The immunopotentiator thymosin alpha-1(Tal)has recently been reported to have anti-inflammatory and neuroprotective functions in rodents.However,how Tα1 affects inflammatory pain remains unclear.In the present study,intraperitoneal injection of Tal attenuated complete Freund's adjuvant(CFA)-induced pain hypersensitivity,and decreased the up-regulation of pro-inflammatory cytokines(TNF-α,IL-1β,and IL-6)in inflamed skin and the spinal cord.We found that CFA-induced peripheral inflammation evoked strong microglial activation,but the effect was reversed by Tα1.Notably,Tα1 reversed the CFA-induced up-regulation of vesicular glutamate transporter(VGLUT)and down-regulated the vesicular γ-aminobutyric acid transporter(VGAT)in the spinal cord.Taken together,these results suggest that Tα1 plays a therapeutic role in inflammatory pain and in the modulation of microgliainduced pro-inflammatory cytokine production in addition to mediation of VGLUT and VGAT expression in the spinal cord.展开更多
目的探讨胸腺肽α1对慢性肺原性心脏病(肺心病)急性加重期的治疗效果。方法100例肺心病急性加重期患者,其PaO2<60 mm Hg(1 mm Hg=0.133 kPa),按治疗药物分为胸腺肽α1组、普通胸腺肽组各50例。2组均予以常规化痰、平喘、抗生素治疗,...目的探讨胸腺肽α1对慢性肺原性心脏病(肺心病)急性加重期的治疗效果。方法100例肺心病急性加重期患者,其PaO2<60 mm Hg(1 mm Hg=0.133 kPa),按治疗药物分为胸腺肽α1组、普通胸腺肽组各50例。2组均予以常规化痰、平喘、抗生素治疗,在此基础上,胸腺肽α1组加用胸腺肽α1 1.6 mg皮下注射,隔日1次;普通胸腺肽组予5%葡萄糖溶液250 ml+普通胸腺肽30 mg静脉滴注,每日1次。分别比较2组患者PaO2升高至60 mm Hg时间、血常规恢复正常时间、呼吸道症状改善时间、2次住院间隔时间,以及治疗期间过敏反应、心原性肝损害发生率等。结果胸腺肽α1组、普通胸腺肽组患者PaO2升高至60 mm Hg的时间分别为(3±2)、(10±3)d(P<0.05),血常规恢复正常时间分别为(5±2)、(14±3)d(P<0.05),呼吸道症状改善时间分别为(3±1)、(10±3)d(P<0.05),2次住院间隔时间分别为(78±3)、(28±3)d(P<0.01);治疗期间发生过敏反应分别为2例(4.0%)、11例(22.0%)(P<0.05),心原性肝损害分别为6例(12.0%)、11例(22.0%)(P>0.05)。结论胸腺肽α1对肺心病急性加重期患者的临床疗效优于普通胸腺肽。展开更多
基金supported by the Foundation for Distinguished Young Talents in Higher Education of Guangdong Province, China (2016KQNCX019 and 2016KQNCX027)the National Natural Science Foundation of China (31571041)+1 种基金the Guangdong Provincial Department of Education Innovating Strong National Engineering Major Project (2014GKXM031)Guangdong Provincial Universities and Colleges Pearl River Scholar Funded Scheme (2016)
文摘Activation of inflammatory responses regulates the transmission of pain pathways through an integrated network in the peripheral and central nervous systems.The immunopotentiator thymosin alpha-1(Tal)has recently been reported to have anti-inflammatory and neuroprotective functions in rodents.However,how Tα1 affects inflammatory pain remains unclear.In the present study,intraperitoneal injection of Tal attenuated complete Freund's adjuvant(CFA)-induced pain hypersensitivity,and decreased the up-regulation of pro-inflammatory cytokines(TNF-α,IL-1β,and IL-6)in inflamed skin and the spinal cord.We found that CFA-induced peripheral inflammation evoked strong microglial activation,but the effect was reversed by Tα1.Notably,Tα1 reversed the CFA-induced up-regulation of vesicular glutamate transporter(VGLUT)and down-regulated the vesicular γ-aminobutyric acid transporter(VGAT)in the spinal cord.Taken together,these results suggest that Tα1 plays a therapeutic role in inflammatory pain and in the modulation of microgliainduced pro-inflammatory cytokine production in addition to mediation of VGLUT and VGAT expression in the spinal cord.
文摘目的探讨胸腺肽α1对慢性肺原性心脏病(肺心病)急性加重期的治疗效果。方法100例肺心病急性加重期患者,其PaO2<60 mm Hg(1 mm Hg=0.133 kPa),按治疗药物分为胸腺肽α1组、普通胸腺肽组各50例。2组均予以常规化痰、平喘、抗生素治疗,在此基础上,胸腺肽α1组加用胸腺肽α1 1.6 mg皮下注射,隔日1次;普通胸腺肽组予5%葡萄糖溶液250 ml+普通胸腺肽30 mg静脉滴注,每日1次。分别比较2组患者PaO2升高至60 mm Hg时间、血常规恢复正常时间、呼吸道症状改善时间、2次住院间隔时间,以及治疗期间过敏反应、心原性肝损害发生率等。结果胸腺肽α1组、普通胸腺肽组患者PaO2升高至60 mm Hg的时间分别为(3±2)、(10±3)d(P<0.05),血常规恢复正常时间分别为(5±2)、(14±3)d(P<0.05),呼吸道症状改善时间分别为(3±1)、(10±3)d(P<0.05),2次住院间隔时间分别为(78±3)、(28±3)d(P<0.01);治疗期间发生过敏反应分别为2例(4.0%)、11例(22.0%)(P<0.05),心原性肝损害分别为6例(12.0%)、11例(22.0%)(P>0.05)。结论胸腺肽α1对肺心病急性加重期患者的临床疗效优于普通胸腺肽。
